Why Theratechnologies (THTX) Shares Are Trading Higher Today - Theratechnologies (NASDAQ:THTX)

Cantor Fitzgerald has initiated coverage on Theratechnologies Inc THTX with an Overweight rating and a price target of $9.
Theratechnologies' two HIV drugs, Egrifta and Trogarzo, could grow 20% a year for the foreseeable future, the analyst writes.
Being conservative, Cantor has modeled a mid-teens sales growth for these two products.
Product innovations and dedicated sales focus on these two drugs have driven uptake.
THTX's decision to internalize its field force and strengthen its commercial operations in the U.S. is starting to deliver results, as evidenced by the 19% Y/Y sales growth in this territory in 3Q22.
For FY22, the company says it is on track to be around $79 million - $82 million, or growth of the commercial portfolio of 13%-17% Y/Y.
Cantor writes that the company's HIV franchise is a source of funds to help build its oncology and NASH pipelines.
In July, Theratechnologies issued an update on the dose escalation portion of the TH1902 Phase 1 safety study.
The data came from 18 heavily pretreated patients with sortilin- (SORT1) expressing cancers.
No Dose Limiting Toxicities were observed during the first cycle.
Price Action: THTX shares are up 18.60% at $2.23 on the last check Thursday.

Theratechnologies Is An Underappreciated HIV-Focused Company, Analyst Says